Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Adjuvant chemotherapy has been proven to reduce significantly the risk for relapse
and death in women with operable breast cancer.In the North American Inter-Group factorial
trial design (CALGB 9741) the concept of dosedense adjuvant chemotherapy was further tested
in patients with node-positive breast cancer.Weekly paclitaxel after standard adjuvant
chemotherapy with epirubicin and cyclophosphamide improves disease-free and overall survival
in women with breast cancer.Investigators asked if dose-dense 2-week intertreatment intervals
(supported by the use of granulocyte-colony stimulating factor) were better than the
conventional inconvenient weekly intervals.